Neurohormonal control of heart failure

Cleveland Clinic Journal of Medicine

Volumn 78, Issue SUPPL. 1, 2011, Pages

  Francis, Gary S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; HEART FAILURE; HUMAN; PATHOLOGY; PSYCHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; HEART FAILURE; HUMANS; NEUROTRANSMITTER AGENTS; PSYCHOPHYSIOLOGY;

EID: 84867172374     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.78.s1.13     Document Type: Article

References (41)

1. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63:645-651.
2. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101:370-377.
3. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982; 49:1659-1666.
4. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20:248-254.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325:293-302.
6. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
7. Pitt B, Zannand F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
8. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
9. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90:1765-1773.
10. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERITHF). JAMA 2000; 283:1295-1302.
11. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106:2194-2199.
12. Imperial ES, Levy MN, Zieske H Jr. Outflow resistance as an independent determinant of cardiac performance. Circ Res 1961; 9:1148-1155.
13. Sonnenblick EH, Downing SE. Afterload as a primary determinant of ventricular performance. Am J Physiol 1963; 204:604-610.
14. Wilcken DE, Charlier AA, Hoffman JI. Effects of alterations in aortic impedance on the performance of the ventricles. Circ Res 1964; 14:283-293.
15. Ross J Jr, Braunwald E. The study of left ventricular function in man by increasing resistance to ventricular ejection with angiotensin. Circulation 1964; 29:739-749.
16. Cohn JN. Blood pressure and cardiac performance. Am J Med 1973; 55:351-361.
17. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819-823.
18. Anand IS, Tam SW, Rector TS, et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 2007; 49:32-39.
19. Rouleau JL, Roecker EB, Tendra M, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 2004; 43:1423-1429.
20. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:2049-2057.
21. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983; 2:755-763.
22. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial-the SAVE Investigators. N Eng J Med 1992; 327:669-677.
23. Curtiss C, Cohn JN, Vrobel T, Franciosa J. Role of the reninangiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978; 58:763-770.
24. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
25. Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM lowleft ventricular ejection trials. Circulation 2004; 110:2618-2626.
26. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
27. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
28. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus lose-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial. Lancet 2009; 374:1840-1848.
29. Packer M. Prospective randomized amlodipine survival evaluation Presented at: 49th American College of Cardiology meeting; March 2000; Anaheim, CA.
30. Pitt B, Zannand F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
31. Pitt B, Remme W, Zannand F, et al. Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
32. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91:2504-2507.
33. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35:569-581.
34. Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilation in patients with asymptomatic systolic dysfunction. Circulation 1993; 88:2277-2283.
35. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of longterm enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 1995; 91:2573-2581.
36. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57:84-95.
37. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91:2504-2507.
38. McDonald KM, Garr M, Carlyle PF, et al. Relative effects of α1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II sub-type 1 receptor blockade on ventricular remodeling in the dog. Circulation 1994; 90:3034-3046.
39. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81:1161-1172.
40. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314:1547-1552.
41. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-310.